Regulatory Story
Go to market news section View chart   Print
Seeing Machines Limited  -  SEE   

Largest single sale of DSS units

Released 07:00 30-Nov-2012

RNS Number : 3738S
Seeing Machines Limited
30 November 2012


Seeing Machines Limited

("Seeing Machines" or the "Company")


Largest single sale of Driver Safety Solution units


Seeing Machines Limited (AIM: SEE) ), the AIM-listed technology company with a focus on vision based human machine interfaces,announces today that a South American distributor, GTD Chile Ingenieria de Sistemas S.A. ("GTD"), has made the largest single sale to date of the Driver Safety Solution ("DSS"), with 180 units for a site in the Atacama desert in Chile.


The site, which is one of the largest producing mines in the world is owned and run by a group of companies including global industry majors.  The first shipment of units has already been dispatched and the remainder will ship and be installed over the coming months. 


GTD was appointed a distributor for DSS with a territory covering Chile, Argentina and Peru in 2011 and had been working with Seeing Machines prior to that to develop the DSS market in the territory. GTD has made numerous sales over the last year and has a number of other significant DSS projects underway.


In addition, Seeing Machines has appointed Paul Johnson, who joined the company in July 2012, as the Senior Vice President for DSS.  Paul's primary focus is to build Seeing Machines' international sales capability and operational delivery capability including support for our distributors in all aspects of the selling, deploying and supporting the DSS.


Pablo Pla, General Manager of GTD commented: "Having worked over the last three years to develop the market here in Chile we are delighted to have secured this sale and see only further growth from this point."

Ken Kroeger, CEO of Seeing Machines commented: "We welcome this sale, especially as a reward for the significant effort GTD has put in to develop the market for the DSS in Chile, and we see this as further validation of our strategy for the DSS.  We have experienced strong year-to-date demand for DSS and continue to see significant growth potential in the resources sector. So far in H1 of FY2013 we have received orders for DSS totalling AUD$4 million, compared to our DSS revenue for Full Year 2012 of AUD$4.9 million."


Seeing Machines Ltd

Ken Kroeger, Managing Director & CEO

+61 (2) 6103 4700

finnCap Ltd

Corporate Finance

 Ed Frisby/Ben Thompson

Corporate Broking

Simon Starr

+44 (0) 20 7220 0500

Walbrook PR Ltd


Helen Westaway (Media Enquiries
Paul Cornelius (Investor Enquiries)

+44 (0)  20 7933 8780


Information for Editors

About Seeing Machines Limited

Seeing Machines is a world leader in the development of premier products and applications that rely on capturing and understanding the behaviour of human faces and eyes. More information is available from our web site:

About Seeing Machines' Driver Safety Solution (DSS)

The Seeing Machines DSS suite is a rugged, non-invasive platform that uses cutting edge face and eye tracking techniques to deliver information on operator fatigue and distraction. The DSS has been specifically designed for deployment into fleets and environments where fatigue and operator distraction pose substantial risk to personnel and equipment and therefore need to be monitored and managed.

For more information on DSS, go to

About Seeing Machines' Fatigue Management Consulting

Seeing Machines supports its DSS technology with professional and scientific fatigue management consulting and training services designed to build understanding of how businesses can reduce the risk of operator  fatigue and support the readiness, implementation and acceptance of its products. Seeing Machines has developed a comprehensive fatigue management framework through combined collaboration with leading fatigue research institutions and hands on experience in the field with organisations who proactively manage fatigue. Seeing Machines also provides detailed fatigue management training for site personnel to better enable them to understand the causes of, and manage their own fatigue. For more information on fatigue management, go to


About Seeing Machines' faceAPI®

faceAPI® allows users to incorporate Seeing Machines world-class face tracking technology into their own products or applications. faceAPI provides a growing suite of image-processing modules created specifically for tracking and understanding faces and facial features. These powerful tracking modules are combined into a complete API toolkit that delivers a rich stream of information that can be incorporated into our customers' own products or services. Seeing Machines faceAPI® delivers a comprehensive, integrated solution for developing products that leverage real-time face tracking. All image-processing for face tracking is handled internally, removing the need for computer vision experience. For more information on faceAPI®, go to

About Seeing Machines' faceLAB®5

Seeing Machines has been creating advanced eye tracking algorithms since the company was founded in 2000. faceLAB®5 is the organisation's eye tracking system that allows researchers to objectively measure human behavior in a wide range of operational conditions and research settings. faceLAB®'s unique eye and facial tracking solution offers users rare flexibility, portability, and accuracy. For more information on faceLAB®, go to

About Seeing Machines' Truefield® Analyzer (TFA)

Currently going through its final clinical trials, the TFA will make objective visual field testing a clinical reality. It combines objectivity with 'non-contact' ease of use, making it easy for technicians and patients, giving clinicians objectivity when assessing their patients' conditions. Assessing both eyes concurrently, TFA tests are fast and can be run in both full-test and screening modes. The tests' bilateral concurrency allows the consensual light reflex to be exploited to identify bilateral asymmetries improving test accuracy. Most importantly, the TFA makes objective perimetry a clinical reality. For more information on TFA, go to


This information is provided by RNS
The company news service from the London Stock Exchange

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.


Largest single sale of DSS units - RNS